Sg3 Management, LLC Chemo Centryx, Inc. Transaction History

Sg3 Management, LLC

  • $0
  • Q3 2023

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 15, 2022
SELL
$15.36 - $27.51 $399,360 - $715,260
-26,000 Reduced 86.67%
4,000 $99,000
Q3 2021

Nov 15, 2021
BUY
$13.18 - $19.83 $342,680 - $515,579
26,000 Added 650.0%
30,000 $513,000
Q4 2020

Feb 16, 2021
SELL
$47.25 - $65.16 $756,000 - $1.04 Million
-16,000 Reduced 80.0%
4,000 $248,000
Q3 2020

Nov 13, 2020
BUY
$46.35 - $61.69 $406,489 - $541,021
8,770 Added 78.09%
20,000 $1.1 Million
Q2 2020

Aug 14, 2020
BUY
$38.58 - $65.07 $433,253 - $730,736
11,230 New
11,230 $646,000

Others Institutions Holding CCXI

# of Institutions
6
Shares Held
66.3K
Call Options Held
0
Put Options Held
0
View Full List

About ChemoCentryx, Inc.

CCXI Quotes by TradingView
  • Ticker CCXI
  • Exchange NASDAQ
  • Shares Outstandng 71,919,696
  • Market Cap $3.68M
  • Description
  • ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil...
More about CCXI
Track This Portfolio

Track Sg3 Management, LLC Portfolio

Follow Sg3 Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sg3 Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Sg3 Management, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email